Scientists are looking into alternative weight loss solutions beyond GLP-1 medications like Mounjaro, Ozempic and Wegovy ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and ...

WW International, the company known as WeightWatchers, brought back its full-year outlook when it reported second-quarter ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Researchers have found a potential game-changing way to help people lose weight and control blood sugar without the unpleasant side effects of today’s popular drugs like Ozempic.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.